who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Philipp Sitter of RepeatMD, Abbey Donnell of Work & Mother, and Chris Howard of Softeq. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to software— recently making headlines in Houston innovation.


Philipp Sitter, founder of RepeatMD

RepeatMD offers its clients rewards-based software and is expanding with a new fintech tool. Photo via LinkedIn

Ever the entrepreneur, Philipp Sitter saw an opportunity to equip health service professionals with marketing tools. RepeatMD, founded in December 2020, specializes in white-label rewards apps for plastic surgeons, medical spas, dermatologists, and similar businesses. Now, it's expanding into the "buy now, pay later" fintech realm through a new deal with BTL Industries, a Marlborough, Massachusetts-based provider of body-sculpting equipment.

Through these services, Sitter sees his company being a one-stop-shop for this type of tech.

"We see us becoming ubiquitous in the industry, where anybody that's a dermatologist, a plastic surgeon, or a medical spa has [our app]," Sitter says. Click here to read more.

Abbey Donnell, founder and CEO of Work & Mother

Abbey Donnell, founder of Work & Mother

Abbey Donnell created a service before employers even knew they needed it. Courtesy of Work & Mother

Abbey Donnell knows she's doing something different. Her company, Work & Mother, builds out and runs lactation suites as an amenity to office buildings.

"We're in a strange niche of the industry. We don't really fall completely into a real estate bucket and we don't fall completely into a tech bucket," Donnell says. "It makes finding investors who really understand what we're doing a little bit trickier."

Despite these challenges, the company has grown and is even eyeing a national expansion. Click here to read more.

Chris Howard, CEO and founder of Softeq

A Houston software company has announced the five early-stage startups it will be supporting through its new venture studio. Photo courtesy of Softeq

A lasting tech ecosystem requires successful tech entrepreneurs to give back to the next generation of new businesses. Chris Howard knows that, and it's why his company, Softeq Development Corporation, announced its inaugural cohort for the Softeq Venture Studio. The program, which will be offered quarterly for four to six startups each cohort, is geared at helping its resident startups quickly develop their technology and build their businesses.

"Historically, most tech startups had a founder with development skills. However, we're now seeing more and more business people, doctors, and other professionals start companies, and they need a strong engineering partner to develop their products," says Christopher A. Howard, Softeq founder and CEO, in a news release.

"We take it several steps further with the Venture Studio providing technology business consulting, development services, and much-needed cash. We're a vested partner, so we also help secure follow-on funding for continued growth," he continues. Click here to read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted